Antidepressant-Like Behavioral and Neurochemical Effects of the Citrus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity. -
Impact of Using Organic Yeast in the Fermentation Process of Wine
processes Article Impact of Using Organic Yeast in the Fermentation Process of Wine Balázs Nagy 1, Zsuzsanna Varga 2,Réka Matolcsi 1, Nikolett Kellner 1 , Áron Szövényi 1 and Diána Nyitrainé Sárdy 1,* 1 Faculty of Horticultural Science Department of Oenology, Szent István University, 1118 Budapest, Hungary; [email protected] (B.N.); [email protected] (R.M.); [email protected] (N.K.); [email protected] (Á.S.) 2 Faculty of Horticultural Science Department of Viticulture, Szent István University, 1118 Budapest, Hungary; [email protected] * Correspondence: [email protected] Abstract: The aim of this study was to find out what kind of “Bianca” wine could be produced when using organic yeast, what are the dynamics of the resulting alcoholic fermentation, and whether this method is suitable for industrial production as well. Due to the stricter rules and regulations, as well as the limited amount and selection of the permitted chemicals, resistant, also known as interspecific or innovative grape varieties, can be the ideal basic materials of alternative cultivation technologies. Well-designed analytical and organoleptic results have to provide the scientific background of resistant varieties, as these cultivars and their environmentally friendly cultivation techniques could be the raw materials of the future. The role of the yeast in wine production is crucial. We fermented wines from the “Bianca” juice samples three times where model chemical solutions were applied. In our research, we aimed to find out how organic yeast influenced the biogenic amine formation of three important compounds: histamine, tyramine, and serotonin. The main results of this study showed that all the problematic values (e.g., histamine) were under the critical limit (1 g/L), although the organic samples resulted in a significantly higher level than the control wines. -
Crofelemer Oral Delayed Release Tablet
Contains Nonbinding Recommendations Draft – Not for Implementation Draft Guidance on Crofelemer This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Crofelemer Dosage Form; Route: Tablet, delayed release; oral Strength: 125 mg Recommendations for the Assessment of Identity and Quality of Botanical Raw Material (BRM): Crofelemer is a botanical drug derived from BRM, the crude red latex of Croton lechleri Müll. Arg. [Fam. Euphorbiacae], which is also called dragon’s blood (sangre de drago). Generic drug applicants should use the same plant species and perform BRM assessment: 1. Crofelemer BRM should be collected from the crude red latex of Croton lechleri. The plant species should be correctly identified and authenticated based on techniques such as macroscopic/microscopic and/or analysis of genetic material. 2. Crude red latex as BRM should be collected from the mature tree with defined eco- geographic regions (EGRs). Implementing and enforcing established good agricultural and collection practice (GACP) procedures will minimize variations in BRM and ensure batch- to-batch consistency of crofelemer. 3. BRMs should be analyzed for their crofelemer content, total phenolics and taspine content, as well as heavy metals and pesticides. Recommendations for Demonstrating API Sameness: API sameness can be established by showing equivalence between Test API and API from the reference listed drug (RLD) product with the three criteria described in detail below. -
Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism -
Management of Chronic Problems
MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use. -
Comparative Pharmacokinetic Study of Luteolin After Oral Administration Of
Vol. 8(16), pp. 422-428, 29 April, 2014 DOI 10.5897/AJPP2013.3835 ISSN 1996-0816 African Journal of Pharmacy and Copyright © 2014 Author(s) retain the copyright of this article Pharmacology http://www.academicjournals.org/AJPP Full Length Research Paper Comparative pharmacokinetic study of luteolin after oral administration of Chinese herb compound prescription JiMaiTong in spontaneous hypertensive rats (SHR) and Sprague Dawley (SD) rats Zhao-Huan Lou1, Su-Hong Chen2, Gui-Yuan Lv1*,Bo-Hou Xia1, Mei-Qiu Yan1, Zhi-Ru Zhang1 and Jian-Li Gao1 1Institute of Material Medica, Zhejiang Chinese Medical University, 548 Binwen Road, Hangzhou, 310053, China. 2Academy of Tradition Chinese Medicine, Wenzhou Medical University, Wenzhou 325035, China. Received 7 August, 2013; Accepted 15 April, 2014 JiMaiTong (JMT), a Chinese herb compound prescription consisted of Flos chrysanthemi Indici, Spica prunellae and Semen cassiae for anti-hypertension. Luteolin is one of the major bioactivity compositions in F. chrysanthemi Indici in JMT. There are some reports about pharmacokinetics of luteolin in extract of F. chrysanthemi and husks of peanut in normal rats, but it lacked pharmacokinetic information of luteolin residing in a Chinese herb compound prescription in hypertensive animal models. The present study aimed to develop a high-performance liquid chromatography with photodiode array detection (HPLC-DAD) method for determination of luteolin in rat plasma and for pharmacokinetic study after oral administration of JMT to spontaneous hypertensive rats (SHR) and normal Sprague Dawley (SD) rats. After oral administration of JMT to SHR and SD rats, respectively the content of luteolin in blood samples at different time points were determined by a reversed-phase high- performance liquid chromatography (RP-HPLC) coupled with liquid-liquid phase extraction. -
Green Tea Extract Ameliorate Liver Toxicity and Immune System Dysfunction Induced by Cyproterone Acetate in Female Rats
Journal of American Science 2010;6(5) Green Tea Extract Ameliorate Liver Toxicity and Immune System Dysfunction Induced by Cyproterone Acetate in Female Rats Heba Barakat Department of Biochemistry and Nutrition,Women`s College, Ain Shams University [email protected] Abstract: Green tea, consumed worldwide since ancient times, is considered beneficial to human health. The present study aimed to evaluate the effect of green tea extract (GTE) on liver damage and immune system function in female rats treated with cyproterone acetate (CPA). Forty healthy female adult albino rats were randomly assigned to four groups. Group (1) was fed on a standard diet as a control. Group (2) was fed on a standard diet and received an intraperitoneally injection of 25mg/Kg/day. Group (3) was fed on a standard diet supplemented with 1 g GTE% and received a daily injection. Group (4) was fed on the supplemented diet for 7 days prior to receiving the daily injection. The experimental duration lasted for 3 weeks initiated from the first injection. The results showed CPA alone led to diminish liver function, hepatic antioxidant enzyme activities and elevated hepatic oxidative stress and serum IgG and IgM levels comparing with the control group of rats. However, the ingestion of GTE either along with or prior to the CPA treatment could significantly improve the function of liver, hepatic oxidative stress and hepatic antioxidant status and elevate the IgG and IgM levels. These data suggested that, GTE possesses a protective effect on the liver against the induced CPA toxicity by increasing auto immunity and countering the hepatic oxidative stress. -
Chrysoeriol Prevents TNF-Induced CYP19 Gene Expression Via EGR-1
International Journal of Molecular Sciences Article Chrysoeriol Prevents TNFα-Induced CYP19 Gene Expression via EGR-1 Downregulation in MCF7 Breast Cancer Cells Dong Yeong Min 1, Euitaek Jung 1, Sung Shin Ahn 1, Young Han Lee 1,2 , Yoongho Lim 3 and Soon Young Shin 1,2,* 1 Department of Biological Sciences, Sanghuh College of Lifesciences, Konkuk University, Seoul 05029, Korea; [email protected] (D.Y.M.); [email protected] (E.J.); [email protected] (S.S.A.); [email protected] (Y.H.L.) 2 Cancer and Metabolism Institute, Konkuk University, Seoul 05029, Korea 3 Division of Bioscience and Biotechnology, BMIC, Konkuk University, Seoul 05029, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-2030-7946 Received: 27 August 2020; Accepted: 9 October 2020; Published: 12 October 2020 Abstract: Estrogen overproduction is closely associated with the development of estrogen receptor-positive breast cancer. Aromatase, encoded by the cytochrome P450 19 (CYP19) gene, regulates estrogen biosynthesis. This study aimed to identify active flavones that inhibit CYP19 expression and to explore the underlying mechanisms. CYP19 expression was evaluated using reverse transcription PCR, quantitative real-time PCR, and immunoblot analysis. The role of transcription factor early growth response gene 1 (EGR-1) in CYP19 expression was assessed using the short-hairpin RNA (shRNA)-mediated knockdown of EGR-1 expression in estrogen receptor-positive MCF-7 breast cancer cells. We screened 39 flavonoids containing 26 flavones and 13 flavanones using the EGR1 promoter reporter activity assay and observed that chrysoeriol exerted the highest inhibitory activity on tumor necrosis factor alpha (TNFα)-induced EGR-1 expression. -
What Is Old Is New…
8/20/2015 WHAT’S COMING DOWN THE PIPELINE? NEWER AND FUTURE ANESTHETIC AND ANALGESIC DRUGS FOR THE SMALL ANIMAL PRACTITIONER. ANESTHESIA AND ANALGESIA Looking for the next “great” tool in the box New drugs and new uses for old drugs Improve patient care and maximize outcomes WHAT IS OLD IS NEW… Methadone Fentanyl (topical) Buprenorphine (transmucosal) Etomidate Meloxicam (transmucosal spray) Robenaxocib 1 8/20/2015 WHAT IS NEW IS NEW… Propoflo 28® (propofol with an increased shelf life) Remifentanil Alenza Simbadol™ ‐ Long acting buprenorphine Alfaxan®‐ CD (alfaxalone) METHADONE Pure µ agonist opioid (synthetic) NMDA antagonist May be best opioid for chronic pain Better analgesic than buprenorphine for 8 hours post operatively Less vomiting and panting than hydromorphone and morphine in dogs Does not seem to elicit aggressive behavior in cats Can be expensive, can not be administered orally (unlike in humans) Dosages Dogs 0.25 to 0.5 mg/kg, IM or IV Cats 0.1 mg/kg, IM or IV FENTANYL (TOPICAL) Recuvyra™ Transdermal solution Topical application in dogs only 50 mg/ml fentanyl (Class II controlled substance) Risk Minimization Action Plan (RiskMAP) Educational materials to veterinarian, staff and owners 2 8/20/2015 FENTANYL (TOPICAL) RiskMAP Owner must read and sign client information sheet before application Only available through a restricted distribution program Certified distributors Veterinarian must take online training prior to being able to purchase High potential for human abuse and safety risks FENTANYL (TOPICAL) Use Administered by two trained veterinarians or staff Protective clothing –gloves, lab coats, and glasses or face shield Applied directly to the skin in the dorsal scapular area. -
Current Perspectives in Herbal and Conventional Drug Interactions
Surana et al. Future Journal of Pharmaceutical Sciences (2021) 7:103 Future Journal of https://doi.org/10.1186/s43094-021-00256-w Pharmaceutical Sciences REVIEW Open Access Current perspectives in herbal and conventional drug interactions based on clinical manifestations Ajaykumar Rikhabchand Surana* , Shivam Puranmal Agrawal, Manoj Ramesh Kumbhare and Snehal Balu Gaikwad Abstract Background: Herbs are an important source of pharmaceuticals. Herbs are traditionally used by millions of peoples for medicine, food and drink in developed and developing nations considering that they are safe. But, interaction of herbs with other medicines may cause serious adverse effects or reduces their efficacy. The demand for “alternative” medicines has been increased significantly, which include medicine derived from plant or herbal origin. The objective of this review article mainly focuses on drug interactions of commonly used herbs along with possible mechanisms. The method adopted for this review is searching of herb-drug interactions in online database. Main text: Herb-drug interaction leads to pharmacological modification. The drug use along with herbs may show pharmacodynamic and pharmacokinetic interactions. Pharmacokinetic interaction causes alteration in absorption, distribution, metabolism and elimination. Similarly, pharmacodynamic interaction causes additive or synergistic or antagonist effect on the drugs or vice versa. Researchers had demonstrated that herbs show the toxicities and drug interactions like other pharmacologically active compounds. There is lack of knowledge amongst physician, pharmacist and consumers related to pharmacological action and mechanism of herb-drug interaction. This review article focuses on the herb-drug interaction of danshen (Salvia miltiorrhiza), Echinacea (Echinacea purpurea), garlic (Allium sativum), ginkgo (Ginkgo biloba), goldenseal (Hydrastis canadensis), green tea (Camellia sinensis), kava (Piper methysticum), liquorice (Glycyrrhiza glabra), milk thistle (Silybum marianum) and St. -
Inhibitory Effects of Phytochemicals on Metabolic Capabilities of CYP2D6*1 and CYP2D6*10 Using Cell-Based Models in Vitro
Acta Pharmacologica Sinica (2014) 35: 685–696 npg © 2014 CPS and SIMM All rights reserved 1671-4083/14 $32.00 www.nature.com/aps Original Article Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro Qiang QU1, 2, Jian QU1, Lu HAN2, Min ZHAN1, Lan-xiang WU3, Yi-wen ZHANG1, Wei ZHANG1, Hong-hao ZHOU1, * 1Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha 410078, China; 2Xiangya Hospital, Central South University, Changsha 410008, China; 3Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China Aim: Herbal products have been widely used, and the safety of herb-drug interactions has aroused intensive concerns. This study aimed to investigate the effects of phytochemicals on the catalytic activities of human CYP2D6*1 and CYP2D6*10 in vitro. Methods: HepG2 cells were stably transfected with CYP2D6*1 and CYP2D6*10 expression vectors. The metabolic kinetics of the enzymes was studied using HPLC and fluorimetry. Results: HepG2-CYP2D6*1 and HepG2-CYP2D6*10 cell lines were successfully constructed. Among the 63 phytochemicals screened, 6 compounds, including coptisine sulfate, bilobalide, schizandrin B, luteolin, schizandrin A and puerarin, at 100 μmol/L inhibited CYP2D6*1- and CYP2D6*10-mediated O-demethylation of a coumarin compound AMMC by more than 50%. Furthermore, the inhibition by these compounds was dose-dependent. Eadie-Hofstee plots demonstrated that these compounds competitively inhibited CYP2D6*1 and CYP2D6*10. However, their Ki values for CYP2D6*1 and CYP2D6*10 were very close, suggesting that genotype- dependent herb-drug inhibition was similar between the two variants. -
Guideline for Preoperative Medication Management
Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.